Screener

Eligibility screening

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

Sponsored by University of California, IrvineStudy detailsClinicalTrials.gov

1 US site in CA

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.